Objectives: This is the first study to compare the safety and efficacy of opium tincture (OT) with methadone for treatment of opioid use disorder.
Because methadone is the most widely administered substitution treatment for opioid use disorder across the globe, opium tincture (OT) has gained increasing popularity in certain countries (Maguet & Majeed, 2010; Mehrjerdi & Zarghami, 2013) . In Iran, approximately 64,000 patients are receiving OT, and OT after methadone (with half a million patients being treated with methadone) is the second most OT is an interesting candidate in Iran and Middle East and the golden triangle region of Southeast Asia for several reasons. First, the retail prices of opium in these areas (0.1-2.1 US dollars per gram) are prominently lower than other parts of the world (22-184 US dollars per gram; United Nations Office on Drugs and Crime, 2011). Second, the major production sites of opium are in these regions, which increases its availability (United Nations Office on Drugs and Crime, 2014) . Third, opium is culturally more acceptable and less stigmatized in these countries, which can result in an increased compliance with the treatment (Zarghami, 2015) . Even more, many patients are inclined towards using OT rather than methadone due to false beliefs and misconceptions about methadone (Daneshmand, Mehrjerdi, & Samiee, 2014) . Finally, limited variety and the side-effect profile of the current treatment options for opioid dependence has provoked continuous investigations for expanding the repository of available treatments.
Considering the scarcity of evidence on safety and efficacy of OT compared with other treatment options (e.g., methadone ; Nikoo et al., 2016) , further investigations are required and may conclude advantages of OT not confined to the above-mentioned regions, but also in other parts of the world.
According to a recent systematic review (Nikoo et al., 2016) , only a few number of reports are available on treatment with OT in patients with opioid use disorder. The three existing randomized clinical trials investigated only detoxification with OT but not its use in the medication-assisted treatment. Beyond that, although OT demonstrated an acceptable retention rate of 71-78% in previous reports, there is no comparison between OT and other standard treatments, in particular methadone, using a controlled design.
| Aims
In this study, we aim to compare the safety and efficacy of OT with methadone for medication-assisted treatment of opioid use disorder for the first time.
| MATERIALS AND METHODS
This protocol paper is prepared based on the Fifth Amendment of the primary protocol. More information is available in Data S1 and at two ICMJE recognized registry databases of clinical trials (ClinicalTrials. gov: NCT02502175; IRCT.ir: IRCT201506261556N78).
| Hypothesis and objectives
The primary objective was to determine if opium tincture is as equally effective as methadone for retaining patients with opioid use disorder in medication-assisted treatment using flexible patient-centered dosing strategy. Our primary hypothesis is that OT is as equally effective as methadone for retaining participants in medication-assisted treatment with opioid use disorder. Our secondary objective is to compare OT and methadone in terms of other health-related outcomes including adverse events, craving, withdrawal symptoms, abstinence from illicit use of drugs, physical health, psychological health, cognitive function, quality of life, cost-effectiveness, and patient satisfaction (Table 1) .
| Research design
In this Phase 3 multicenter, parallel group, double-blind, noninferiority randomized clinical trial (Food and Drug Administration, 2016) , patients with opioid use disorder were randomized to receive either opium tincture or methadone using a patient-centered flexible dosing strategy for 12 weeks, complying with the Iranian National Protocol 
| Sampling, eligibility, and recruitment
Recruitment centers were primarily four private outpatient medication-assisted treatment clinics located in major cities in Iran: Sari and Tehran in the north, Isfahan in the center, and Shiraz in the south. The Tehran center dropped out due to an inability to recruit participants. We later added a rural center in Sari. To achieve the target sample size, brochures and flyers were distributed in community outreach, general and mental hospitals, nongovernmental organization (NGO)-run communities, colleges and universities, drop-in centers, and specialized clinics for treatment of participants with HIV and hepatitis C. In addition, flyers were posted on the billboard of bus/subway and local stores as well as in the above mentioned places. The recruitment period was from July 2017 to January 2018.
Participants provided informed consent before any study-related procedure. It was required that eligible participants be willing and able to adhere to the treatment protocol based on their consent and assessment by the experienced physician at each clinic. Participants were selected from patients with opioid use disorder based on the Participants were excluded if they met any of the following criteria: active participation in another treatment program for opioid use disorder within the last 14 days before inclusion in this study; severe hepatic impairment; hypersensitivity to methadone, opium, or their ingredients; pregnancy; severe chronic respiratory disease; head injuries and raised intracranial pressure; biliary tract disease; and consumption of monoamine oxidase inhibitors within the last 14 days prior to the study.
| Randomization, allocation concealment, and blinding
Participants were randomized with a 1:1 allocation ratio to methadone or OT treatment arms using stratified randomization block technique with block sizes of 2 and stratification on sex (female/male ratio = 1/ 9). This stratification is based on gender distribution of the population and assessors were only aware of the randomization code for each participant, but not the allocation label or randomization tables. An essence was added to methadone syrups to make them similar to opium tincture in terms of smell, color, and taste. No biological test that could potentially unbind the treatment was planned in this study.
Randomization and allocation concealment would be broken in emergency situations at the discretion of the responsible physician.
| Treatment interventions
After obtaining informed consent, participants who fulfilled the eligibility criteria were invited for Baseline Visit. In this visit, participants were assessed using several assessment batteries in a structured clinical interview and then randomized into either opium tincture (10 mg/ ml) or methadone (5 mg/ml) treatment arms. Both treatments were manufactured by DaruPakhsh.co, Tehran, Iran, in accordance with instructions provided by the World Health Organization on Good Manufacture Practice. The essence was added to the methadone syrup after strict laboratory evaluations for stabilization and lack of interaction with other ingredients. Also, the volume of the essencecontained methadone syrups was controlled during production, not to be different from normal methadone syrups in terms of concentration of active ingredients. Medications were monitored regularly by the pharmacist at each center. Patients received their treatment based on patient-centered flexible dosing strategy using the following flowcharts where one unit of medication is equal to 1 ml (10 mg) of opium tincture or 0.5 ml (2.5 mg) of methadone ( Figure 1 ). The treatment would be discontinued in case the participant voluntarily chose not to continue, or the research physician decided to discontinue the treatment based on predefined criteria discussed in the safety section.
All the relevant assessments, treatments, and laboratory tests were free of charge for all participants. Furthermore, all the participants received routine psychological therapies provided by the psychologist at the clinic based on an individual's need. Also, participants received concomitant prescription medications other than opioids on a need basis according to the physician's opinion and instructions. The type, duration, and reason for all the psychological therapies and prescribed medications were documented.
2.6 | Outcomes, instruments, and timeline Table 2 and Figure 2 represent the study schedule as well as participants' flow throughout the study. In brief, patients had 30 visits during the 12 weeks from the point they started their treatment. Table 1 demonstrates study outcomes as well as methods for their assessment.
| Primary outcome

Retention in treatment
Retention in treatment is defined as participating in a certain proportion of scheduled treatment sessions to receive their medications.
Because frequencies of visits were different in various stages of the study, we had to set the cut-off for each stage separately. A previous study had defined retention in treatment as receiving treatment for 10 out of the last 14 (71.4%) days of follow-up period 
| Secondary outcomes
Key secondary outcomes are craving, withdrawal symptoms, abstinence from illicit use of drugs, physical health, psychological health, cognitive function, severity of problems related to substance use, client satisfaction, and cost-effectiveness. Behavioral stages of change and childhood traumatic experiences were measured at baseline. 
| Setting and personnel
The trial centers were private outpatient centers that fulfilled the personnel and equipment requirements set by national guidelines. Each center had a director, one full-time general practitioner, one full-time psychologist, one full-time pharmacist, and one secretary. They were equipped with outpatient as well as basic emergency care facilities.
All research physicians had at least 5 years of experience in treatment of patients with opioid use disorder. Also, clinical psychologists were experienced and/or trained in the implementation of assessment batteries used in this study.
2.8 | Quality assurance, data collection, monitoring, and confidentiality
At each study center, the staff were trained by investigators on the Tri-council Policy Statement 2 and Ethics Code of Iran, as well as for appropriate methods of assessment, completion of case report forms (CRF), and data management procedures using face to face lectures 
Regression method and role playing with the staff. Independent entities at the data center reviewed confirmed CRFs, and would contact the clinics for clarification if incomplete or inaccurate data were found in CRFs.
Data were collected on paper (i.e., CRF). Paper documents are kept in a locked place in the clinic office with authorized access. Electronic data were entered into a safely secured, encrypted, and password-protected database with regular synching and back-ups.
All documents will be kept in the treatment center for 25 years after completing the study, after which paper forms will be shredded and electronic data will be permanently deleted.
A unique study code not derived from or related to the information about the individual was used on all study documents except randomization lists, consent form, and screening log. This code cannot be translated to identify the individual and investigators or their institutions could not use or disclose the unique study code for other purposes or disclose the mechanism for re-identification. Participant medical information obtained during the study is confidential and disclosure to third parties is prohibited. No identifying participant information, including names, will be disclosed in reports, publications, or presentations. At the participant's written request, medical information may be given to his/her personal physician.
Access to data and associated documentation will be permitted only if user agrees to use the data for research purpose, commit to confidentiality principles, and destroy the data after completing the analyses. Principal investigator, coinvestigators and clinic staff in Iran will have direct access to paper forms.
2.9 | Consent, safety, and adverse events 
| Feasibility
Feasibility review was conducted after recruitment of first 60
patients. The interim analysis was carried out once and reported to the DSMB. Accordingly, the DSMB could make decision on any necessary changes to the ongoing protocol concerning patients' safety or data integrity after discussing the issue with investigators. Recommendations would be made to principal investigators regarding continuation, modification, or termination of the trial in case of serious safety concerns or devaluation of clinical equipoise that justified the initiation of the trial.
| Sample size
The sample size was calculated using the FDA guidelines for noninferiority clinical trials using a fixed margin (95%-95%) approach (Food and Drug Administration, 2016) . To calculate the active control effect, data was obtained from a Cochrane systematic review in which, retention in treatment with methadone has been compared with placebo.
The meta-analysis of the four new studies has yielded a pooled 95%
confidence interval for retention ratio of methadone to placebo of 4. 44 [3.26, 6 .04] (Mattick et al., 2009 and assuming a power of 90% and Type I error is set at 5%, the total sample size was calculated to be 240 participants, 120 in each group. Due to limitation of resources for continuing the trial, we decided to adjust the sample size with the power of 80%, which yielded a sample size of 174: Given the existing resources, clinics agreed to continue the recruitment up to a sample size of N = 204, which surpasses the power of 80% but did not reach the power of 90% as set initially.
| Statistical analysis
Analyses will be based on both intent-to-treat and per-protocol methods. A confidence interval procedure will be conducted to evaluate whether the upper bound of 95% confidence interval of the retention ratio of methadone to OT passes the noninferiority margin, that is, 1.25. Multiple Imputation by Chained Equations will be used for missing data when comparing score changes between the two treatment arms. Outliers will be identified based on the distribution of outcomes and will not be included in further analysis unless confirmed for accuracy of data collection and entry. Sensitivity analyses will be used to address the impact of missing data on conclusions (Nikoo et al., 2016 ).
This study is also subject to some limitations. First, we stratified our sample based on the age and gender distributions of patients with opioid dependence in Iran, with men to women ratio of 9:1 and almost half the sample selected from patients with age range of 30-39 years old, which may be different from other countries (United Nations
Office on Drugs and Crime, 2010). Second, although we used every effort to make the two treatments similar, patients might be able to guess the treatment they receive based on the characteristics that is different between OT and methadone, such as the timing and intensity of resultant euphoric effect. Third, providing free medication and care might increase the retention in treatment in both groups compared with usual treatment settings.
Among the strengths of this study are a large enough sample size and the comprehensive battery of assessments with repeated measurements. Furthermore, this clinical trial is unique in that it provides a potential basis for estimation of conversion ratio between methadone and opium tincture for treatment of opioid use disorder.
In more details, because the scant evidence on optimum dosing 
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